Flashcard library · Medicine & Health · PaperFren
Digital pills cut blood pressure faster
Patients with uncontrolled hypertension and type 2 diabetes using digital medicines had larger 4-week SBP drops than usual care.
Keep what you just learned
Save these 11 cards to your NoteFren library. Your first review starts right away, and each card links back to the study it came from.
What was the primary endpoint?
Change in SBP from baseline to week 4.
Source: Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial · DOI · quote verified
How much greater was the SBP drop with DMO?
About 9 mm Hg greater reduction by 4 weeks vs usual care.
Source: Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial · DOI · quote verified
What was the modified-ITT sample?
109 participants (40 + 40 DMO arms, 29 usual care).
Source: Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial · DOI · quote verified
What LDL-C differences were reported?
−33.2 at week 4 and −19.2 at week 12 versus usual care.
Source: Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial · DOI · quote verified
Where and how was the pilot run?
12-week open-label cluster-randomized three-arm pilot at 13 outpatient sites in CA and CO.
Source: Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial · DOI · quote verified
Why use cluster randomization?
To keep providers treating only one assigned arm and reduce investigator bias.
Source: Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial · DOI · quote verified
What HbA1c pattern was noted?
DMO showed trends toward greater HbA1c reduction (up to ~1% greater).
Source: Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial · DOI · quote verified
How many were enrolled before exclusions?
118 participants across 13 sites.
Source: Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial · DOI · quote verified
What population mix was highlighted?
Many low-income (56.9%) and Hispanic (52.3%) participants.
Source: Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial · DOI · quote verified
Which conditions defined eligibility focus?
Uncontrolled hypertension and type 2 diabetes.
Source: Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial · DOI · quote verified
What clinical risks motivate treating both conditions?
Major risks for cardiac disease, stroke, and kidney disease.
Source: Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial · DOI · quote verified